Company Insights
Total employees
7.2% from last year
This is some text inside of a div block.
New hires (YTD)
5% of total workforce
Departments
650 in Engineering
Locations
5,012 in New York, NY
- Vertex Pharmaceuticals is a leading biotech company specializing in cystic fibrosis (CF) treatments, with recent FDA approval for ALYFTREK® and TRIKAFTA® expanding eligibility to approximately 95% of CF patients in the U.S.
- In 2025, Vertex reported total revenue of $12.0 billion, a 9% increase from 2024, and forecasts 2026 revenue between $12.95 billion and $13.1 billion, driven by ongoing innovation and product launches.
- Vertex has established partnerships and is advancing its pipeline with new therapies, including Casgevy for sickle cell disease and povetacicept for IgAN, enhancing its market presence beyond CF.
- The ideal buyer for Vertex's products includes healthcare providers and institutions treating CF patients, as well as those addressing genetic disorders, making it crucial for sales teams to engage with stakeholders in these therapeutic areas now.
Get more information on people & companies with Unify
